NDATOPICALAEROSOL, FOAM
Approved
Oct 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
9
Data completeness
5/8 — Partial
SORILUX (calcipotriene) by Molecular Devices is clinical pharmacology in humans, the natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin d 3 (cholecalciferol) in the skin. First approved in 2010.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SORILUX is a topical foam formulation of calcipotriene, a synthetic vitamin D3 analog, approved in 2010 for psoriasis treatment. It works by binding to vitamin D receptors to regulate skin cell proliferation and differentiation. The product is absorbed minimally (approximately 6% of applied dose) with rapid metabolism to inactive compounds.
$0.351MPart D
LOE ApproachingDeclining
1.5 years to LOEWith LOE approaching in 1.6 years and minimal current Medicare utilization ($351K spending in 2023), the brand team is likely in maintenance or transition mode with limited growth opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D 3 (cholecalciferol) in the skin. Calcipotriene is a synthetic analog of vitamin D 3 . Clinical studies with…
Pharmacologic Class:
Vitamin D Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
Started Jun 2023
291 enrolled
Plaque Psoriasis
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
Started Apr 2017
699 enrolled
Scalp Psoriasis
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
Started Jul 2013
147 enrolled
Psoriasis Vulgaris
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
Started Apr 2013
36 enrolled
Psoriasis
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
Started Jan 2013
63 enrolled
Psoriasis
Worked on SORILUX at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.